Related Experiment Video

Updated: May 11, 2026

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
12:24

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy

Published on: September 29, 2016

Synthesizing oncogenic signal-processing systems that function as both "signal counters" and "signal blockers" in

Yuchen Liu1, Weiren Huang, Dexi Zhou

  • 1Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Sungang Road, Shenzhen 518039, China.

Molecular Biosystems
|April 27, 2013
PubMed

Insights

Synthetic biology systems harness RNA-protein interactions to quantify oncogenic signals in cancer cells. These novel bio-systems act as "signal counters" and "blockers," inhibiting cancer growth while sparing normal cells.

Area of Science:

  • Synthetic biology
  • Molecular biology
  • Cancer research

Background:

  • RNA-protein interactions regulate eukaryotic translation.
  • Artificial biological systems can leverage these interactions.
  • Oncogenic signaling pathways are crucial in cancer development.

Purpose of the Study:

  • To design and test a synthetic biological system for quantifying oncogenic signals.
  • To evaluate the system's potential for cancer treatment.
  • To compare the system's performance against traditional methods.

Main Methods:

  • Constructed a synthetic system with Renilla and Firefly luciferase reporters.
  • Engineered vectors targeting nuclear factor-κB (NF-κB) and β-catenin pathways.
  • Quantified oncogenic signal intensity by measuring luciferase expression inhibition.
  • Assessed the system's impact on cancer cell proliferation and apoptosis.

Main Results:

  • Luciferase expression inhibition correlated with targeted protein levels, enabling quantitative oncogenic signal measurement.
  • The system effectively inhibited oncogenic signal downstream gene expression in cancer cells.
  • Demonstrated cancer cell proliferation inhibition and apoptosis induction without affecting normal cells.
  • Achieved highly accurate, consistent, and reproducible quantification, outperforming ELISA and immunoblotting.

Conclusions:

  • The developed synthetic systems function as both "signal counters" and "signal blockers" in cancer cells.
  • This approach offers a novel synthetic biology platform for oncogenic signal measurement.
  • The systems show promise for targeted cancer treatment and discriminating cancerous from non-cancerous cells.

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System09:55

All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System

Published on: December 20, 2021

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...